Annual Report And Financial Statements

Overview

The report describes 2022 as a breakthrough year for ANGLE, with FDA De Novo clearance for the Parsortix PC1 Clinical System, described as the first FDA product clearance for harvesting intact cancer cells from patient blood. It reports a 95.4% AUC result from a 200-patient ovarian cancer study and continued expansion of its clinical laboratories and pharma services. Sustainability highlights include a new mental health awareness programme, trained mental health first aiders, flexible working and ISO 15189 accreditation, while the company notes that its sustainability data framework is still being developed.

Document

Report type: Annual Report with Sustainability Disclosures
Class: Embedded
Scope: Full report
Fiscal year: 2022
Period: Ends 31 December 2022
Language: English
Pages
File size

Materiality

Assessment
Basis

Assurance

Statement included

Data Services

Turn sustainability reports into a dataset built for your research.

From bulk PDFs to structured indicators and machine-readable documents.

View services